Skip to main content
. 2023 Jun 24;15:137. doi: 10.1186/s13098-023-01102-0

Table 2.

Hazard Ratios for HF According to MAFLD Status and its subgroups

Case/Participants Incidence (/1, 000 person years) HR (95%CI)
Model 1 Model 2 Model 3
Total
Non-MAFLD 1945/67,930 2.19(2.09,2.28) reference reference reference
MAFLD 1315/30,755 3.29(3.12,3.47) 1.51(1.40,1.62) 1.52(1.42,1.63) 1.40(1.30,1.50)
Group by the degree of fatty liver
Non-MAFLD 1945/67,930 2.19(2.09,2.28) reference reference reference
Mild MAFLD 809/20,035 3.10(2.90,3.32) 1.41(1.30,1.53) 1.43(1.31,1.55) 1.33(1.23,1.45)
Moderate MAFLD 412/8775 3.62(3.29,3.99) 1.66(1.50,1.85) 1.68(1.50,1.86) 1.51(1.35,1.68)
Severe MAFLD 94/1945 3.77(3.08,4.61) 1.82(1.50,2.24) 1.85(1.50,2.27) 1.57(1.28,1.94)
Group by type of metabolic disorder
Non-MAFLD 1945/67,930 2.19(2.09,2.28) reference reference reference
MAFLD1* 895/24,590 2.77(2.59,2.96) 1.31(1.21,1.42) 1.33(1.22,1.43) 1.27(1.17,1.38)
MAFLD2* 37/1107 2.64(1.91,3.64) 1.09(0.79,1.51) 1.10(0.79,1.52) 1.12(0.81,1.55)
MAFLD3* 383/5058 6.14(5.56,6.79) 2.42(2.17,2.70) 2.43(2.18,2.71) 1.95(1.73,2.20)

*MAFLD1: BMI ≥ 23 kg/m2 without diabetes

MAFLD2: BMI < 23 kg/m2 with at least two metabolic abnormalities but not diabetes

MAFLD3: type 2 diabetes mellitus

Model 1: adjusted for age, gender;

Model 2: adjusted for all the variables in model 1 and Smoking, Drinking, Education level, Salt status and Physical activity;

Model 3: adjusted for all the variables in model 2 and Antihypertensive treatment, Antidiabetic treatment and Lipid-lowering treatment